00:26 , Jul 20, 2019 |  BC Extra  |  Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
00:43 , Jun 22, 2019 |  BC Extra  |  Financial News

WuXi stocks tumble as Rubio continues to press China agenda

WuXi Biologics and WuXi AppTec ended down about 6% in Hong Kong on Friday, losing a combined $765 million in market cap, as Sen. Marco Rubio (R-Fla.) continued to ratchet up pressure on China's life...
00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
12:34 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

The generic antifungal ciclopirox inhibits HBV C protein to treat HBV infection

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis B virus (HBV) Cell culture and mouse studies suggest inhibiting HBV C with ciclopirox could help treat HBV infection. Screening of 978 FDA-approved drugs in a cell-based HBV replication...
21:42 , May 28, 2019 |  BC Extra  |  Politics & Policy

World Health Assembly adopts drug price transparency resolution

Countries will be more likely to require manufacturers to disclose drug prices and costs associated with their development and commercialization, after an agreement was reached by members of the World Health Assembly on Tuesday. The...
20:53 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Trivalent vaccination confers protection against three equine encephalitis viruses

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis Cell culture, mouse and macaque studies suggest a trivalent vaccine based on multiple proteins from Eastern, Western and Venezuelan equine encephalitis viruses could help prevent encephalitis caused by the...
15:40 , May 10, 2019 |  BC Extra  |  Clinical News

Polyphor valuation cut in half on halted Phase IIIs of antibiotic murepavadin

Polyphor lost CHF12.27 (48%) to CHF13.38 on Friday after announcing late Thursday that it suspended enrollment in a pair of Phase III trials of pneumonia antibiotic murepavadin (POL7080) after observing a higher-than-expected incidence of acute...
23:12 , Apr 24, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:53 , Mar 20, 2019 |  BC Innovations  |  Translation in Brief

Sangamo’s ZFN linkers finger new options

Sangamo is using new linkers to expand the structural variety of the ZFNs it designs and increase the odds of finding ZFNs with high editing efficiency and specificity for their targets. Conventional zinc finger nucleases...